
Personalized Medicine: A Faustian Bargain?
Therapies tailored to an individual's particular genetic makeup could be highly effective—but they could also be too expensive for many of those whose DNA donations go into creating the treatments
Eleonore Pauwels is a Senior Research Associate with the Science and Technology Innovation Program at the Woodrow Wilson International Center for Scholars. Her primary focus is a comparative and critical analysis of the EU and US approaches towards the societal governance of synthetic biology. She is also examining the challenges that new forms of biotechnology pose for political and public policy organizations, and the regulatory innovations that emerge alongside developments in cutting edge genomics and biotechnologies. Her research focuses on responsible innovation, risk communication, citizen participation in research and technical controversies, as well as knowledge-sharing between epistemic cultures within and outside of the laboratory.
Jim Dratwa is a global fellow with the Wilson Center and head of Ethics in Science and New Technologies within the Bureau of European Policy Advisers. His research and publications address the interconnections between knowledge, values and action. Dratwa has held several positions at the European Commission and now heads the ethics sector in BEPA (the Bureau of European Policy Advisers to the President of the European Commission) and acts as EC representative in the relevant organizations dealing with the ethical implications of science and new technologies (OECD, Council of Europe, UN agencies).

Personalized Medicine: A Faustian Bargain?
Therapies tailored to an individual's particular genetic makeup could be highly effective—but they could also be too expensive for many of those whose DNA donations go into creating the treatments

How Identity Evolves in the Age of Genetic Imperialism
From designer babies to women whose genitals smell like peaches, 2014 graced us with a taste of the hope, hype and superficiality of business as usual in Silicon Valley.